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Entry of human immunodeficiency type 1 virus (HIV-1) into target cells requires both CD4and
one of the chemokine receptors. Viruses predominantly use one, or occasionally both, of the
major co-receptors CCR5 and CXCR4, although other receptors, including CCR2B and CCR3,
function as minor co-receptors. A 32-nucleotide deletion (∆32) within the β-chemokine receptor
5 gene (CCR5) has been described in subjects who remain uninfected despite extensive exposition
to HIV-1. The heterozygous genotype delays disease progression. This allele is common among
Caucasians, but has not been found in people of African or Asian ancestry. A more common
transition involving a valine to isoleucine switch in transmembrane domain I of CCR2B (64I),
with unknown functional consequences, was found to delay disease progression but not to reduce
infection risk. As the Brazilian population consists of a mixture of several ethnic groups, we
decided to examine the genotype frequency of these polymorphisms in this country. There were
11.5% CCR5 heterozygotes among the HIV-1 infected population and 12.5% among uninfected
individuals, similar to data from North America and Western Europe. The prevalence of CCR2-
64I homozygotes and heterozygotes was 0.06 and 15.2%, respectively, also similar to what is
known for North America and Western Europe.
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Attachment of HIV-1 to cells is mediated between
specific sequences of the gp120 envelope glycoprotein
and the CD4 receptor, which normally is a receptor for
the major histocompatibility complex class II (MHC-II)
molecules. Although the CD4 is the best-known receptor,
it alone is not sufficient for HIV-1 entry into cells.
Evidence suggesting additional receptors first came from
the fact that HIV-1 could not efficiently replicate in other
animal cells engineered to express human CD4 [1]. The
discovery of co-receptors for HIV-1 entry, such as
CXCR4, CCR5, CCR2, and CCR3, which are chemokine
receptors, have provided insights into this phenomenon [2].
 Physiologically, chemokine receptors mediate the
chemotaxis of T-cells and phagocytes to areas of
inflammation [3]. Upon ligand binding, the receptors
transduce an intracellular signal that results in the rapid
mobilization of intracellular calcion. Each of the eight
known chemokine receptors is a G protein with a
characteristic pattern of ligand binding [3,4]. The
receptor CCR5, which also serves as a major co-
receptor for macrophage-tropic HIV-1 virus, binds the
β-chemokines RANTES (regulated on activation,
normal T expressed and secreted), MIP-1α
(macrophage inflammatory protein) and MIP-1β [5].
The ligands for CCR2, which also serves as a minor
co-receptor for HIV-1 entry, are MCP-1, 2, 3, 4, and
5 (monocyte chemoattractant protein) [6].
In fact, different HIV-1 strains have distinct cell
tropisms; viruses with T-cell tropism utilize the CXCR4
co-receptor, while those with selective macrophage-
monocyte tropism utilize the CCR5 or CCR2 co-
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receptors [2,7]. The strain usually involved in the
primary infection – macrophage-tropic isolates – is the
strain that uses the CCR5 or CCR2 co-receptors
expressed on mucosal dendritic cells. The more
cytopathic (SI) T-cell-tropic strains that evolve during
the course of infection, and that precipitate accelerated
T-cell depletion and progression to AIDS, utilize the
CXCR4 receptor. “Dual tropic” HIV-1 strains appear
during the course of infection; such strains may be
intermediates between macrophage- and T-cell-tropic
populations. This transition in cell tropism, involving viral
adaptation, which enables broader co-receptor use,
may be a key step in progression to AIDS [7].
Another insight that came from the discovery of
co-receptors is the observation that a few individuals
remain unaffected by HIV-1 despite multiple high-
risk sexual exposures to the virus [8-10]. It has been
shown that the CD4+ T-cells of these individuals are
highly resistant in vitro to the entry of primary
macrophage-tropic virus, but are readily infected with
transformed T-cell-line-adapted viruses [11].
Subsequent to this discovery, a 32-base pair deletion
(∆32) in the CCR5 gene was identified in some
Caucasians [12,13]. This mutated allele causes
truncation of the CCR5 co-receptor on lymphoid cell
surfaces. In the homozygous state, this truncated allele
is epidemiologically related to the resistance of some
highly exposed individuals to HIV-1 infection. An
association of delayed disease progression with
CCR5 ∆32 has also been reported [14]. The
frequency of the allele CCR5 ∆32 has been estimated
in various ethnic groups [14]. Among Caucasians,
approximately 15% are heterozygotes and 1% are
homozygotes. In contrast, the deleted allele is rare among
persons of African, Asian and Hispanic origin [14].
The polymorphisms in the CCR2 gene involve a
point mutation that results in a switch from valine to
isoleucine at transmembrane protein position 64,
described as CCR264I. One major study [14] found
a correlation between CCR2B 64I polymorphisms and
disease progression, although these findings were not
confirmed by a second study [15]. Nonetheless,
CCR2B 64I polymorphisms have no protective effect
against HIV-1 infection [14,15].
Brazil is considered an ethnically diverse country,
with individuals of Caucasian, African, Asian and native
American origin, and interracial marriages are common.
We decided to analyse CCR5 and CCR2B
polymorphisms in this population.
We made a cross-sectional molecular epidemiology
study to determine the prevalence of individuals
homozygous and heterozygous for the mutation coding
for the 32-pair deletion in the CCR5 chemokine receptor
gene (CCR5 ∆32), and for a valine to isoleucine switch
in transmembrane domain I of CCR2B (CCR2 64I).
Materials and Methods
Clinical samples. One hundred and eighty-three HIV-
1-positive samples were obtained from outpatient clinics
at the Federal University of São Paulo in São Paulo,
Brazil. We also analyzed 115 samples from women
with unknown HIV-1 status, as a control group. These
samples were taken in accordance with the ethics
standards of the Ethics Committee of the Federal
University of São Paulo and with the Helsinki
Declaration of 1975, revised in 1983.
DNA purification. DNA was extracted from frozen
whole blood using a QIAamp Blood Kit (QIAGEN
Inc, Santa Clarita, CA), using the methodology
indicated by the manufacturer.
CCR5 genotyping. A portion of the CCR5 gene was
amplified by PCR from genomic DNA and analyzed on a
5% Acrylamide gel, yielding a 189 bp fragment for the
wild type allele, and a 157 bp fragment for the deleted
allele (Figure 1A). PCR primers flanking the 32-nucleotide
deletion were 5’ CAA AAA GAA GGT CTT CAT TAC
ACC 3’, and 5’ CCT GTG CCT CTT CTT CTC ATT
TCG 3’, as described previously [5]. The PCR reaction
mixture the final 100 µL contained 50 mM MgCl2, 10
mM of dNTPs, 20 pmol of each primer, and 0.5 unit of
Taq Polymerase in 1X reaction buffer (Gibco BRL,
Gaithersburg MD). Each PCR amplification consisted of
40 cycles, with five cycles of 94oC for 1 min, 55oC for 1
min, and 72oC for 1.5 min, followed by 35 cycles of 94oC
for 30s, 60oC for 30s, and 72oC for 45s.
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CCR2 genotyping. Amplification of a portion of the
CCR2 gene by PCR was performed with primers 5’
TTG TGG GCA ACA TGa TGG, which has a cytosine
substituted by an adenine (in lower case) and 5’ GAG
CCC ACA ATG GGA GAG TA, as described
previously [14]. The final 128-bp product was
analyzed for Restriction Fragment Length
Polymorphisms (RFLP) using Bsa BI enzyme, which
generated 110- and 18 bp fragments when an
isoleucine was present instead of a valine at position
64 in CCR2. These products were genotyped in a
5% acrylamide gel (Figure 1B).
Results
To determine the frequency of polymorphism of the
CCR5 gene, 183 HIV-1-infected individuals were
tested at the Medical School of São Paulo. One
hundred percent of the samples were positive by PCR.
Consistent with previous findings, the analysis in the
5% acrylamide gel showed that none of the infected
subjects were homozygous for the ∆32 allele (∆/∆).
The frequency of heterozygotes (∆/+) in this population
was 11.5%, while 88.5% were wild type (+/+) for the
deletion (21 and 162 individuals, respectively). The
control population was also investigated to compare
these data with possibly uninfected individuals. These
samples were obtained from a population at risk for
HIV-1 infection; 115 women were included in this study.
The results were similar to those found in Caucasian
populations in North America and western Europe:
homozygous - 0%, heterozygous – 12.5% and wild
type – 87.5% (Table 1).
The same sample of infected individuals was
investigated for CCR2 gene polymorphism. PCR
positivity was 97.27%. Analysis of the control group
was deemed unnecessary since the prevalence of
CCR2 64I seems to be the same in infected and
uninfected individuals. One individual among the 178
enrolled in this study was homozygous (64I/64I) for
the 64I genotype - 0.56%, 27 were heterozygous
(64I/+) - 15.17%, and 150 were wild type (+/+) -
84.26% (Table 1).
Discussion
Although anecdotical cases of HIV-positive
CCR5∆32 homozygous individuals have been
described [16,17], numerous epidemiological studies
have confirmed that the absence of full-length CCR5
confers protection to HIV infection. Recent studies
of transfusion recipients and hemophiliacs indicate
Table 1. Genotypic frequency of the CCR5 and CCR2 polymorphisms in a HIV-1 infected (CCR5 and CCR2)
and a control population (CCR5). The wild type CCR5 is represented by (+), whereas the 32 base pair deletion
is represented bt ∆. The wild type CCR2 is represented by (+), and the valine to isoleucine substitution at position
64 is represented by 64I.
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CCR5 Genotype
∆ / ∆ ∆/+(%) +/+(%) Total (%)
Control (HIV-1 status unknown) 0 15 (13.0) 100 (87.0) 115 (100%)
Infected (HIV-1 seropositive) 0 21 (11.5) 162 (88.5) 183 (100%)
CCR2 Genotype
64I/64I (%) 64I/+ (%) +/+ (%) Total (%)
Infected (HIV-1 seropositive) 1 (0.6) 27 (15.17) 150 (88.5) 178 (100%)
BJID 2003; 7 (August) 239
that this resistance occurs when the parenteral route
is involved [18].
More recently, a second mutation in CCR5 that has
a prevalence of 1% in the European population was
described. A single-base-pair mutation, m303,
introduces a stop codon that prevents cell surface
expression of a functional CCR5 receptor. Thus, m303
homozygosity, or its association with the CCR5 ∆32
allele, could account for some of the unexplained cases
of HIV-1 resistance in individuals who carry an
apparent wild type CCR5 or who are heterozygous
[21]. Polymorphism of other genes coding for other
co-receptors related to MT strain infection, such as
CCR2, apparently have no influence on the incidence
of HIV-1 infection.
There is also a relationship between genetic
polymorphism in host cell co-receptors and disease
progression. The onset of AIDS seems to be
postponed in individuals heterozygous for the CCR5
∆32 allele [14,19,20]. However, identification of the
heterozygous condition for CCR5 accounts for only a
small proportion of the long-term non-progressors that
remain AIDS-free for 10 to 20 years after HIV-1
infection. As an example, more than 60% of long-term
non-progressors are homozygous for the common allele
CCR5+/+ [13]. The other chemokine receptor gene,
CCR2, also has some degree of polymorphism that
might be related to disease progression. A point
mutation, CCR2 64I, occurs at an allele frequency of
10 to 15% among Caucasians and African Americans.
Data from one large cohort indicate that HIV-1 infected
individuals carrying this allele progressed to AIDS two
to four years later than individuals homozygous for the
common allele [14], whereas another study failed to
detect this association [18].
This is the first description of the prevalence of
CCR5 and CCR2 polymorphisms in a Brazilian
population. The Caucasian pattern of CCR5 allele
Figure 1. Analyses of CCR5 and CCR2B amplification.
A. CCR5 was amplified by PCR from genomic DNA of
outpatient clinics and in the control group. Primers that flank
the deletion were used to generate wild-type and deleted
fragments of 189bp and 157bp, respectively. The position of
the wild-type (3,4) and heterozygous deleted fragments (1,2)
is indicated by arrows in the 5% acrylamide gel. Sizes of marker
fragments (MW) are indicated to the right in base pairs.
B. Genomic DNA from outpatient clinics and the control group
was amplified by PCR to generate 128bp fragments. The final
product was digested by Bsa BI enzyme, which generated 110
and 18bp fragments when an isoleucine was present instead
of a valine at position 64 in CCR2B. These products were
separated in the 5% acrylamide gel. This gel shows wild-type
fragments in wells 1 and 3, and fragments heterozygous and
homozygous for the genotype change in wells 2 and 4,
respectively. Sizes of marker fragments (MW) are indicated to
the left in base pairs.
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polymorphism prevails in this population, even though
is a great deal of ethnic mixture in this country.
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